絞り込み

17876

広告

Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033.

著者 Heinrich M , Rankin C , Blanke CD , Demetri GD , Borden EC , Ryan CW , von Mehren M , Blackstein ME , Priebat DA , Tap WD , Maki RG , Corless CL , Fletcher JA , Owzar K , Crowley JJ , Benjamin RS , Baker LH
JAMA Oncol.2017 Feb 09 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (11view , 0users)

Full Text Sources

Medical

Miscellaneous

After identification of activating mutations of the KIT gene in gastrointestinal stromal tumor (GIST)-the most common sarcomaof the gastrointestinal tract-a phase 2 study demonstrated efficacy of imatinib mesylate in patients with metastatic GIST harboring a KIT exon 11 mutation. Initial results of long-term follow-up have found a survival benefit in this subgroup of patients.
PMID: 28196207 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード